Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 690 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
8 Results
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
- Sarcoma Cancers
- Cancer
- Gender:All Genders
- Age:18 years and older
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Sarcoma Cancers
- Brain & Other Nervous System Cancers
- Eye Cancers
- Lymphoma
- Kidney Cancer
- Leukemia & Hematologic Cancers
- Liver Cancer
- Gastrointestinal Cancers
- Thyroid & Other Endocrine Cancers
- Gynecological Cancers
- Male Genital Cancers
- Lung Cancer
- Skin Cancers & Melanoma
- Bladder Cancer
- Colorectal Cancer
- Pediatric Cancers
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
- Sarcoma Cancers
- Kidney Cancer
- Pediatric Cancers
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Sarcoma Cancers
- Gender:All Genders
- Age:18 years and older
SSc Arm Fat Quantification Study
- Orthopaedics, Muscle & Bone
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient
- Phase 1 Cancers
A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors
- Phase 1 Cancers
The SIGNAL Study
- Children's Health
- Respiratory System